首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Integrating Forecast Probabilities in Antibiograms: a Way To Guide Antimicrobial Prescriptions More Reliably?
【2h】

Integrating Forecast Probabilities in Antibiograms: a Way To Guide Antimicrobial Prescriptions More Reliably?

机译:将预测概率整合到抗菌素中:一种更可靠地指导抗菌素处方的方法?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Antimicrobial susceptibility testing (AST) assigns pathogens to “susceptible” or “resistant” clinical categories based on clinical breakpoints (CBPs) derived from MICs or inhibition zone diameters and indicates the likelihood for therapeutic success. AST reports do not provide quantitative measures for the reliability of such categorization. Thus, it is currently impossible for clinicians to estimate the technical forecast uncertainty of an AST result regarding clinical categorization. AST error rates depend on the localization of pathogen populations in relation to CBPs. Bacterial species are, however, not homogeneous, and subpopulations behave differently with respect to AST results. We addressed how AST reporting errors differ between isolates with and without acquired drug resistance determinants. Using as an example the beta-lactams and their most important resistance mechanisms, we analyzed different pathogen populations for their individual reporting error probabilities. Categorization error rates were significantly higher for bacterial populations harboring resistance mechanisms than for the wild-type population. Reporting errors for amoxicillin-clavulanic acid and piperacillin-tazobactam in Escherichia coli infection cases were almost exclusively due to the presence of broad-spectrum- and extended-spectrum-beta-lactamase (ESBL)-producing microorganisms (79% and 20% of all errors, respectively). Clinicians should be aware of the significantly increased risk of erroneous AST reports for isolates producing beta-lactamases, particularly ESBL and AmpC. Including probability indicators for interpretation would improve AST reports.
机译:抗菌药物敏感性测试(AST)根据源自MIC或抑制区直径的临床断点(CBP)将病原体划分为“易感”或“耐药”临床类别,并指出治疗成功的可能性。 AST报告没有提供量化方法来确保此类分类的可靠性。因此,目前临床医生无法估计有关临床分类的AST结果的技术预测不确定性。 AST错误率取决于与CBP相关的病原体种群的定位。然而,细菌种类不是同质的,并且亚群在AST结果方面表现不同。我们研究了有和没有获得性耐药因素的分离株之间AST报告错误的差异。以β-内酰胺类化合物及其最重要的抗性机制为例,我们分析了不同病原体种群的单个报告错误概率。具有抗性机制的细菌种群的分类错误率显着高于野生型种群。在大肠杆菌感染病例中报告阿莫西林-克拉维酸和哌拉西林-他唑巴坦的错误几乎完全是由于存在产生广谱和广谱β-内酰胺酶(ESBL)的微生物(分别占79%和20%)错误)。临床医生应意识到产生β-内酰胺酶的分离株,特别是ESBL和AmpC的分离株的AST报告错误的风险大大增加。包括解释可能性的指标将改善AST报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号